OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
BOTHELL, WA and VANCOUVER, March 28, 2013
BOTHELL, WA and VANCOUVER, March 28, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott Cormack,
President and Chief Executive Officer, will provide a corporate presentation
at the Future Leaders in the Biotech Industry Conference on Friday, April 5,
2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York City.
A live audio webcast can be accessed through the Investor Relations page of
the OncoGenex website atwww.oncogenex.com. The webcast replay will be
archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com
SOURCE OncoGenex Pharmaceuticals, Inc.
Investor Relations Contact:
Press spacebar to pause and continue. Press esc to stop.